Maximon launches 100 million Longevity Co-Investment Fund

The Longevity Co-Investment Fund finances longevity-focussed start-up companies launched by company-builder Maximon.

Switzerland-based Maximon has announced the launch of its Longevity Co-Investment Fund (LCIF), which already had its first closing in the founder’s share class at CHF 6 million.

The Fund invests in venture companies founded by Maximon, the Swiss longevity company builder, which are promoting longevity and healthy aging with supporting research in esteemed universities as well as with their products and services or which support an active and healthy aging in society. The Fund’s first investments include longevity supplement company AVEA and longevity advisory and big data company Biolytica.

Longevity.Technology: Music tells us that love can build a bridge, but Maximon have shown that venture building is equally as effective, especially when it comes to bridging the gap between science and business. As a company builder, Maximon identifies the most promising business opportunities in the field of longevity and operationally works with entrepreneurs to build longevity ventures from scratch by providing proven structures, financing and an inspiring playground for entrepreneurs, empowering them to build impactful, science-based and scalable companies that provide healthy aging and rejuvenation solutions.

The Maximon Team is already responsible for two IPOs, various double and triple digit exits and has raised more than CHF 2b (over $2.15b) investment capital. 
Maximon launches 100 million Longevity Co-Investment Fund
Longevity is the science of antiaging research and rejuvenation and has experienced an unprecedented advancement over recent years, particularly with the discovery that the rate of aging is controlled and can be modulated, at least to some extent, by genetic pathways and biochemical processes. Longevity identifies both lifestyle and pharmaceutical targets to improve the human healthspan.

Dr Tobias Reichmuth, Founding Partner at Maximon, says: “Longevity is the new big investment opportunity. There is simply nobody who wouldn’t want to age in good health. Need I say more?”

Maximon Founding Partner Marc P Bernegger adds: “The recent progress in extending and enforcing a healthy lifespan is very impressive and creates unique and massive investment opportunities. We already have substantial subscription requests for the fund’s next closing”.

The Longevity Co-Investment Fund (LCIF) invests up to CHF 10 million per company, which allows to finance up to 10-12 start-ups in this fast growing industry over the next four years. The LCIF will remain open for investors for the next 18+ months, and we’ll be watching with interest!

No spam - just the good stuff

Subscribe to our newsletter